Innovative Medicines Innitiative (IMI)

The Innovative Medicines Initiative Joint Undertaking (IMI Joint Undertaking) supports collaborative research to improve the entire development process and make it more efficient, accelerating patients' access to better and safer medicines. Its function is none other than to promote the development of medicines, facilitating open collaboration in research.


Calls are published regularly on the innitiative's website.


Council Regulation 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking |  DOUE L 169/54 de 7.6.2014

General information

Tagged as:

You may also be interested

EU companies doubled R&D investment growth in 2022

Europe's industry significantly increased its investment in research and development in 2022, according to the 2023 edition of the EU Industrial Research & Development (R&D) Investment Scoreboard. EU private R&D investment growth has reached the highest rate since 2015 and more than doubled compared to 2021, with 13.6% increase in 2022. In comparison, China has […]
RAPID, IP/23/6532, 14.12.2023

Bio-printing of living cells for regenerative medicine

Horizon Europe. Research and Innovation Actions. Tools and technologies for a healthy society. Bio-printing of living cells for regenerative medicine. Call for proposals HORIZON-HLTH-2024-TOOL-11-02.
W3 Funding & Tender Opportunities, 26.10.2023